M
M. Dror Michaelson
Researcher at Harvard University
Publications - 133
Citations - 21191
M. Dror Michaelson is an academic researcher from Harvard University. The author has contributed to research in topics: Renal cell carcinoma & Sunitinib. The author has an hindex of 44, co-authored 121 publications receiving 19079 citations. Previous affiliations of M. Dror Michaelson include Yeshiva University & University of Michigan.
Papers
More filters
Journal ArticleDOI
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
Robert J. Motzer,Thomas E. Hutson,Piotr Tomczak,M. Dror Michaelson,Ronald M. Bukowski,Olivier Rixe,Stéphane Oudard,Sylvie Negrier,Cezary Szczylik,Sindy T. Kim,Isan Chen,Paul Bycott,Charles M. Baum,Robert A. Figlin +13 more
TL;DR: Progression-free survival was longer and response rates were higher in patients with metastatic renal-cell cancer who received sunitinib than in those receiving interferon alfa.
Journal ArticleDOI
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
Robert J. Motzer,Thomas E. Hutson,Piotr Tomczak,M. Dror Michaelson,Ronald M. Bukowski,Stéphane Oudard,Sylvie Negrier,Cezary Szczylik,Roberto Pili,Georg A. Bjarnason,Xavier Garcia-del-Muro,Jeffrey A. Sosman,Ewa Solska,George Wilding,John A. Thompson,Sindy T. Kim,Isan Chen,Xin Huang,Robert A. Figlin +18 more
TL;DR: Sunitinib demonstrates longer overall survival compared with IFN-alpha plus improvement in response and progression-free survival in the first-line treatment of patients with metastatic RCC, highlighting an improved prognosis in patients with RCC in the era of targeted therapy.
Journal ArticleDOI
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
Brian I. Rini,Bernard Escudier,Piotr Tomczak,Andrey Kaprin,Cezary Szczylik,Thomas E. Hutson,M. Dror Michaelson,Vera Gorbunova,Martin Gore,Igor G. Rusakov,Sylvie Negrier,Yen Chuan Ou,Daniel Castellano,Ho Yeong Lim,Hirotsugu Uemura,Jamal Tarazi,David Cella,Connie Chen,Brad Rosbrook,Sinil Kim,Robert J. Motzer +20 more
TL;DR: Axitinib is a treatment option for second-line therapy of advanced renal cell carcinoma and resulted in significantly longer progression-free survival (PFS) compared with sorafenib.
Journal ArticleDOI
Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma
Robert J. Motzer,M. Dror Michaelson,Bruce G. Redman,Gary R. Hudes,George Wilding,Robert A. Figlin,Michelle S. Ginsberg,Sindy T. Kim,Charles M. Baum,Samuel E. DePrimo,Jim Z. Li,Carlo L. Bello,Charles P. Theuer,Daniel J. George,Brian I. Rini +14 more
TL;DR: The genetics of RCC and these promising clinical results support the hypothesis that VEGF and PDGF receptor-mediated signaling is an effective therapeutic target in RCC, as second-line therapy in a setting where no effective systemic therapy is presently recognized.
Journal ArticleDOI
Sunitinib in Patients With Metastatic Renal Cell Carcinoma
Robert J. Motzer,Brian I. Rini,Brian I. Rini,Ronald M. Bukowski,Brendan D. Curti,Daniel J. George,Gary R. Hudes,Bruce G. Redman,Kim Margolin,Jaime R. Merchan,George Wilding,Michelle S. Ginsberg,Jennifer Bacik,Sindy T. Kim,Charles M. Baum,M. Dror Michaelson +15 more
TL;DR: The results of this trial demonstrate the efficacy and manageable adverse-event profile of sunitinib as a single agent in second-line therapy for patients with cytokine-refractory metastatic clear-cell RCC.